Effects of Tolperisone on Measures of Drowsiness and Cognitive Function
A Randomized, 4-Period, Crossover Study to Investigate the Effects of Tolperisone on Measures of Drowsiness and Cognitive Function Compared to Cyclobenzaprine and Placebo
Sponsor: Neurana Pharmaceuticals, Inc.
Listed as NCT04407377, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Neurana Pharmaceuticals, Inc., it has been updated 10 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE1
-
May 2021 — Feb 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Neurana Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .